Safety Assessment of Lactobacillus Salivarius CECT5713 in 6 Months Old Children

NCT ID: NCT00724204

Last Updated: 2008-07-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-04-30

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the trial is to evaluate safety of a follow on formula supplemented with Lactobacillus salivarius CECT5713. A randomized double blind placebo controlled trial was carried out. Eighty six months old children were recruited by the department of pediatrics of Hospital Univeristario San Cecilio. Children were divided in two groups that consumed a follow on formula supplemented or not with the probiotic strain during 6 months. Fecal samples were obtained at the recruitment, at 3 months and at the end of the trial. In addition revision by the pediatrician was performed once a month and possible adverse effects were recorded both by the pediatrician and by parents.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Children that consumed a follow on formula without Lactobacillus salivarius CECT5713

Group Type PLACEBO_COMPARATOR

follow on formula without probiotics

Intervention Type DIETARY_SUPPLEMENT

A follow on formula without probiotics

B

Children that consumed a follow on formula with Lactobacillus salivarius CECT5713

Group Type ACTIVE_COMPARATOR

follow on formula with Lactobacillus salivarius CECT5713

Intervention Type DIETARY_SUPPLEMENT

follow on formula with Lactobacillus salivarius CECT5713 in a dose of 2x10E8 cfu/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

follow on formula without probiotics

A follow on formula without probiotics

Intervention Type DIETARY_SUPPLEMENT

follow on formula with Lactobacillus salivarius CECT5713

follow on formula with Lactobacillus salivarius CECT5713 in a dose of 2x10E8 cfu/day

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy six months old children

Exclusion Criteria

* Lactose intolerance
* Cow's milk protein allergy
* Serious metabolic diseases
* Antibiotic treatment
* Serious gastrointestinal diseases
Minimum Eligible Age

6 Months

Maximum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Clinico Universitario San Cecilio

OTHER

Sponsor Role collaborator

Puleva Biotech

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Puelav Biotech

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

José A Maldonado, PhD, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Pediatrics. Hospital Universitario San Cecilio

Mónica Olivares, PhD

Role: STUDY_CHAIR

Department of Nutrition and Health. Puleva Biotech. Granada

Federico Lara-Villoslada, PhD

Role: STUDY_DIRECTOR

Department of Nutrition and Helath. Puleva Biotech. Granada

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Universitario San Cecilio

Granada, Granada, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Maldonado J, Lara-Villoslada F, Sierra S, Sempere L, Gomez M, Rodriguez JM, Boza J, Xaus J, Olivares M. Safety and tolerance of the human milk probiotic strain Lactobacillus salivarius CECT5713 in 6-month-old children. Nutrition. 2010 Nov-Dec;26(11-12):1082-7. doi: 10.1016/j.nut.2009.08.023. Epub 2009 Dec 16.

Reference Type DERIVED
PMID: 20018483 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Safety Salivarius

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Infant Colic Treatment With Probiotics
NCT03467334 COMPLETED PHASE2
Prebiotic Effects in Healthy Toddlers
NCT05783141 RECRUITING NA